0001098972 False 0001098972 2021-11-09 2021-11-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares



Washington, D.C. 20549





Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

November 9, 2021
Date of Report (Date of earliest event reported)



(Exact name of registrant as specified in its charter)


(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

3 Forbes Road

Lexington, MA 02421

(Address of Principal Executive Offices) (Zip Code)

(781) 674-4400

(Registrant's telephone number, including area code)


(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per shareAGENThe Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 9, 2021, Agenus Inc. announced its financial results for the quarter ended September 30, 2021. In connection with the announcement, the Company issued a press release, which is being furnished as Exhibits 99.1 to this current report on Form 8-K.

The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated November 9, 2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 9, 2021By: /s/ Christine M. Klaskin        
  Christine M. Klaskin
  VP, Finance


EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling


Agenus Corporate Update and Third Quarter 2021 Financial Report

  • Clinical results presented at SITC show that AGEN1181, as a monotherapy and in combination with balstilimab, shows durable responses in 9 cancer types, including patients whose cancers have recurred following PD-1 therapy
  • Agenus will commence Phase 2/3 trials of AGEN1181 and balstilimab in colorectal and several gynecological cancers
  • Agenus’ cell therapy affiliate, MiNK Therapeutics (NASDAQ: INKT), launched as a publicly traded company with >$40 million raised to accelerate clinical development
  • AGEN1777, an Fc-enhanced TIGIT bispecific antibody, entered Phase 1 development, triggering a $20M milestone payment from Bristol Myers Squibb
  • After successfully achieving clinical milestones and passing FDA inspections, Agenus withdrew its BLA for balstilimab based on FDA guidance; given the clinical benefit demonstrated by balstilimab, Agenus plans to launch an expanded access program in several countries

LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the third quarter of 2021.

“With more than 100 patients treated with our Fc-enhanced CTLA-4 antibody, AGEN1181, we are very encouraged by the clinical responses achieved across tumor types. Of note, we are seeing responses in patients who have failed to respond to all other treatment, including PD-1 inhibitors,” said Garo Armen, PhD, Chairman and Chief Executive Officer of Agenus. “We will be presenting detailed trial results at the SITC conference this week. We have also successfully completed an initial public offering for MiNK Therapeutics, and have launched our adjuvant business, SaponiQx.”

AGEN1181 (Fc-enhanced CTLA-4), as a monotherapy and in combination with balstilimab (anti PD-1), shows clinical benefit in 9 cold and treatment-resistant tumor types; data to be presented at SITC

  • First presentation of clinical data from 100+ patients who represent a heavily pre-treated population, and were administered AGEN1181 as a monotherapy or in combination with balstilimab
  • Evidence of AGEN1181 monotherapy activity with multiple confirmed responses: microsatellite stable (MSS) - endometrial cancer (CR), melanoma (PR), cervical cancer (PR), and pancreatic cancer (PR), with the former three responses occurring in tumors which failed to respond to anti-PD-1 therapy
  • Additional responses in patients treated with AGEN1181 in combination with balstilimab, including in cold, poorly immunogenic tumors. These include:
    • Microsatellite stable colorectal cancer (MSS-CRC): 2 confirmed PRs, 2 unconfirmed PRs, and 7 stable disease (SD) among 17 evaluable patients for a disease control rate of 65%
    • Gynecological malignancies: 2 PRs, 3 SDs among 6 evaluable ovarian cancer patients; 1 PR and 1 unconfirmed PR in MSS-endometrial cancer
    • Other tumors: 2 unconfirmed responses in visceral angiosarcoma, and one unconfirmed response in PD-1-relapsed/refractory NSCLC
  • Majority of responses are durable and ongoing, with additional data to be presented at SITC on November 12th (Abstract # 479)
  • Both monotherapy and combination therapy were well tolerated, with no cases of hypophysitis or pneumonitis
  • Based on these data, Agenus will commence Phase 2/3 trials evaluating AGEN1181, as a monotherapy and in combination with balstilimab, in colorectal and gynecological cancers

MiNK Therapeutics launched an IPO; its stock is trading on NASDAQ

  • MiNK Therapeutics launched a successful IPO, raising >$40M to support the rapid clinical development of its allogeneic cell therapies
  • MiNK has three presentations planned at SITC, which will showcase data on clinical-stage, allogeneic, iNKT cell therapy (AgenT-797), including clinical persistence and activity, preclinical anti-tumor activity and tissue distribution, as well as the tumor killing potential of engineered iNKT cells generated by leveraging a proprietary CAR platform

SaponiQx launch to accelerate development of proven and novel adjuvants, as well as optimized antigen-adjuvant constructs

  • Will address global need for vaccines offering long-lasting efficacy with secure production, which has been amplified by the current pandemic
  • QS-21 Stimulon™ adjuvant is proven to drive durable immunity - SHINGRIX® (GSK zoster vaccine, recombinant) offers protection of >9 years
  • Collaborating with Phyton Biotech and Ginkgo Bioworks to develop and optimize a plant cell culture method of manufacturing QS-21 and next-generation saponin- based adjuvants for a secure and sustainable adjuvant supply

First patients dosed in multiple collaborator programs

  • First patient dosed with AGEN1777, our Fc-enhanced TIGIT bispecific antibody licensed to BMS, triggering a $20 million milestone payment. BMS intends to advance AGEN1777 in high-priority indications, such as non-small cell lung cancer
  • First patient dosed in clinical collaboration with Nelum, evaluating our first-generation CTLA-4, zalifrelimab, in combination with Nelum’s hedgehog inhibitor and chemotherapy in first-line pancreatic cancer

Planning underway to launch expanded access programs for balstilimab

  • BLA for balstilimab in second-line cervical cancer was withdrawn after full approval of pembrolizumab, four months ahead of the FDA goal date, based on data for pembrolizumab plus chemotherapy in first-line setting
  • Agenus will discontinue the confirmatory trial, resulting in a >$100M expense reduction
  • As balstilimab met trial endpoints with ORR of 20% in PD-L1 positive tumors and 8% in PD-L1 negative tumors, Agenus plans to launch an expanded access program in several countries, including the US, pending regulatory processes
  • Combination of balstilimab and zalifrelimab resulted in a near doubling of responses (33% vs. what has been reported with pembrolizumab in PD-L1+ cervical cancer patients); data was presented at this year’s ESMO Conference

Third Quarter 2021 Financial Results

We ended the third quarter of 2021 with a cash and short-term investment balance of $262 million as compared to $100 million at December 31, 2020.

For the third quarter ended September 30, 2021, our cash provided by operations was $131 million and we reported a net income of $177 million or $0.76 per share basic and $0.72 per share diluted. This compares to cash used in operations for the same period in 2020 of $32 million and a net loss of $52 million or $0.28 per share basic and diluted.

Our cash provided by operations for the nine-months ended September 30, 2021 was $33 million with net income of $39 million or $0.19 per share basic and $0.18 per share diluted, compared to cash used in operations of $104 million and a net loss for the same period in 2020 of $145 million or $0.87 per share, basic and diluted. Non-cash operating expenses for the nine-months ended September 30, 2021 were $46 million compared to $35 million for the same period of 2020.

We recognized revenue of $275 million and $57 million for the nine-months ended September 30, 2021 and 2020, respectively, which includes revenue related to upfront license fees received and milestones earned, non-cash royalties, and revenue recognized under our collaboration agreements.

Financial Highlights     
(in thousands, except per share data)     
     September 30, 2021 December 31, 2020    
Cash, cash equivalents and short-term investments$261,528  $99,871      
     Three months ended September 30, Nine months ended September 30, 
      2021   2020   2021   2020  
Revenues, research and development $238,986  $4,286  $242,265  $24,283  
Revenues, non-cash royalty   12,593   8,947   28,903   29,950  
Revenues, other    1,375   1,599   4,236   2,673  
Total Revenue    252,954   14,832   275,404   56,906  
Research and development expenses  42,937   32,134   125,122   107,048  
General and administrative expenses  21,385   14,380   54,388   39,188  
Cost of service revenue   817   911   2,589   1,545  
Other expense (income)   162   939   (1,207)  2,805  
Non-cash interest expense   16,298   15,918   48,295   44,109  
(Gain) loss related to debt   (6,197)  -   (6,197)  2,720  
Non-cash contingent consideration fair value adjustment 275   2,196   13,531   4,652  
Net income (loss)   $177,277  $(51,646) $38,883  $(145,161) 
Net income (loss) per share attributable to Agenus Inc. common stockholders, basic$0.76  $(0.28) $0.19  $(0.87) 
Net income (loss) per share attributable to Agenus Inc. common stockholders, diluted$0.72  $(0.28) $0.18  $(0.87) 
Cash provided by (used in) operations$ 131,373  $ (31,626) $ 33,072  $ (103,506) 
Non-cash operating expenses  $4,337  $14,375  $46,321  $35,181  

Conference Call
Tuesday, November 9, 2021, 8:30am ET
Dial-in numbers: (833) 614-1394 (US) or (914) 987-7115 (International); Conference ID: 8585893.

A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/mr7ep4vu.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its affiliate MiNK Therapeutics), adjuvants, and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to the use of therapeutic candidates AGEN1181, zalifrelimab, balstilimab AGEN1777, and iNKT cell therapy (AgenT-797) , for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety profile of the therapeutic candidates, both alone and in combination with each other and/or other agents (e.g., AGEN1181 in combination with balstilimab); statements relating to future clinical and regulatory development plans for therapeutic candidates alone and in combination with other agents, including AGEN1181 in combination with balstilimab; statements relating to our ability to obtain regulatory approval for our therapeutic candidates, including the timing (including the possibility of accelerated review) and scope of any such regulatory approval; statements relating to our ability to launch expanded access programs; statements relating to future commercial plans, including those related to the receipt of future milestone payments and collaboration and license arrangements; statements relating to our ability to develop novel adjuvants and accelerate the development of adjuvants, as well as statements relating to our ability to develop optimized antigen-adjuvant constructs and develop and optimize manufacturing methods for QS-21 and other adjuvants; statements relating to planned savings; ; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Agenus Inc.
Divya Vasudevan, PhD

Agenus Media Relations
Kimberly Ha
KKH Advisors

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 f8k_110921_htm.xml IDEA: XBRL DOCUMENT 0001098972 2021-11-09 2021-11-09 iso4217:USD shares iso4217:USD shares 0001098972 false 8-K 2021-11-09 AGENUS INC. DE 000-29089 06-1562417 3 Forbes Road Lexington MA 02421 781 674-4400 false false false false Common Stock, $0.01 par value per share AGEN NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Nov. 09, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2021
Entity File Number 000-29089
Entity Registrant Name AGENUS INC.
Entity Central Index Key 0001098972
Entity Tax Identification Number 06-1562417
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3 Forbes Road
Entity Address, City or Town Lexington
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02421
City Area Code 781
Local Phone Number 674-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol AGEN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_110921.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_110921.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_110921.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_110921.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_110921.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-21-007714-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-21-007714-xbrl.zip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end